DC
TSHA icon

Davenport & Co’s Taysha Gene Therapies TSHA Stock Holding History

Davenport & Co’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-27,170
Closed -$101K – 1033
2022
Q2 		$101K Sell
27,170
-500
-2% -$1.98K ﹤0.01% 963
2022
Q1 		$180K Hold
27,670
– – ﹤0.01% 1004
2021
Q4 		$322K Sell
27,670
-55,100
-67% -$831K ﹤0.01% 886
2021
Q3 		$1.54M Buy
82,770
+69,020
+502% +$1.31M 0.01% 443
2021
Q2 		$292K Sell
13,750
-6,400
-32% -$148K ﹤0.01% 802
2021
Q1 		$409K Buy
+20,150
New +$546K ﹤0.01% 576

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Davenport & Co's TSHA Position: Q3 2022 in Review

Davenport & Co sold out of Taysha Gene Therapies (TSHA) in Q3 2022, closing a stake of 27,170 shares — an estimated $101K sold.

Davenport & Co first reported a position in TSHA in Q1 2021 and held it in 6 quarters. The position peaked at $1.54M in Q3 2021. 54 funds tracked by Wall St. Rank hold TSHA as of Q3 2022.

  • Davenport & Co reported no remaining Taysha Gene Therapies position as of Q3 2022 after selling out during the quarter.
  • Davenport & Co sold 27,170 Taysha Gene Therapies shares in Q3 2022, an estimated $101K.
  • Davenport & Co first reported a position in Taysha Gene Therapies in Q1 2021 and held it in 6 quarters.
  • Davenport & Co's Taysha Gene Therapies position peaked at $1.54M in Q3 2021.
  • 54 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2022.

Based on Davenport & Co's 13F filing for Q3 2022, filed 11 Oct 2022.